The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.

TitleNoggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.
Publication TypeJournal Article
Year of Publication2018
AuthorsPolyzos, S. A., Kountouras J., Anastasilakis A. D., Makras P., Hawa G., Sonnleitner L., Missbichler A., Doulberis M., Katsinelos P., & Terpos E.
JournalHormones (Athens)
Volume17
Issue4
Pagination573-579
Date Published2018 Dec
ISSN2520-8721
KeywordsCarrier Proteins, Case-Control Studies, Drug Therapy, Combination, Humans, Mineralocorticoid Receptor Antagonists, Non-alcoholic Fatty Liver Disease, Spironolactone, Vitamin E
Abstract

AIM: The evaluation of (a) noggin levels in patients with simple steatosis (SS) vs. nonalcoholic steatohepatitis (NASH) vs. controls, and (b) the effect of combined spironolactone plus vitamin E vs. vitamin E monotherapy on noggin levels in biopsy-proven patients with nonalcoholic fatty liver disease (NAFLD).
METHODS: In the case-control study, 15 patients with SS, 16 with NASH, and 24 controls were included. In the randomized controlled trial, NAFLD patients were assigned to vitamin E (400 IU/d) or spironolactone (25 mg/d) plus vitamin E for 52 weeks.
RESULTS: Noggin levels were lower in SS (5.8 ± 1.5 pmol/l) and NASH (8.7 ± 2.4 pmol/l) patients than in controls (13.7 ± 2.7 pmol/l; p for trend = 0.040), but were similar in SS and NASH patients. After adjustment for potential cofounders, log(noggin) remained different between groups. Log(noggin) levels similarly increased post-treatment in both groups: log(noggin) was not different between groups (p = 0.20), but increased within groups over time (p < 0.001), without a significant group × time interaction (p = 0.62). Log(noggin) significantly increased at month 2 post-treatment (p = 0.008 vs. baseline) and remained stable thereafter.
CONCLUSIONS: Lower noggin levels were observed in NAFLD patients than in controls. Noggin levels increased similarly by either combined low-dose spironolactone plus vitamin E or vitamin E monotherapy.
TRIAL REGISTRATION: NCT01147523.

DOI10.1007/s42000-018-0083-8
Alternate JournalHormones (Athens)
PubMed ID30467685

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.